Loading stock data…
TEM
$48.62+0.03 (+0.06%)
Market OpenUpdated 3:40 PM EDT
Tempus AI, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tempus AI, Inc. in the Healthcare sector is trading at $48.62 with a market capitalization of $8.5B. Wall Street consensus targets $66.53 (15 analysts), implying a +36.8% move over the next 12 months. The stock is currently near its 52-week low of $41.73, remaining 25.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +36.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$48.62
Potential Downside
0%
Whystock Fair Value$48.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Buy
Mean target$66.53+36.8%
Range$35.00 – $100.00
Fundamentals
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytic...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.74%
Volume
Today's trading volume
6.13M
Recent News
Assessing Tempus AI (TEM) Valuation After Recent Share Price Rebound And Underpriced Growth Narrative
Market snapshot and recent moves Tempus AI (TEM) has drawn fresh attention after a strong single-day move, with the stock up about 10% on the latest close at US$52.26, compared with weaker returns over the past month. See our latest analysis for Tempus AI. That move comes after mixed momentum over the year, with the 7 day share price return of 1.89% set against a year to date share price decline of 16.2% and a 1 year total shareholder return that is down 10.91%. Recent strength is emerging...
Tempus (TEM) Gets Double-Digit Boost from New Partnerships
Tempus AI Inc. (NASDAQ:TEM) is one of the 9 Stocks Crushing the Market With Surging Returns. Tempus AI saw its share prices jump by 10 percent on Thursday to finish at $52.56 apiece, as investors cheered its formation of a consortium alongside two health institutions to support the development of an open-source digital pathology platform […]
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades
In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...